• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Trials in the Key of G: Building Level 1 Evidence on the Real-world Effectiveness of Prostate Biomarkers.G 调试验：构建前列腺生物标志物真实世界有效性的一级证据。
Eur Urol Focus. 2022 Jul;8(4):897-900. doi: 10.1016/j.euf.2022.08.001. Epub 2022 Aug 10.
2
Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort.用于预测高危前列腺切除队列中前列腺癌死亡率的经验证的临床和基因组风险分层工具的综合价值。
Eur Urol. 2015 Feb;67(2):326-33. doi: 10.1016/j.eururo.2014.05.039. Epub 2014 Jul 2.
3
A genomic classifier improves prediction of metastatic disease within 5 years after surgery in node-negative high-risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy.一种基因组分类器可改善接受根治性前列腺切除术且无辅助治疗的淋巴结阴性高危前列腺癌患者术后 5 年内发生转移性疾病的预测。
Eur Urol. 2015 Apr;67(4):778-86. doi: 10.1016/j.eururo.2014.10.036. Epub 2014 Nov 12.
4
Translating a Prognostic DNA Genomic Classifier into the Clinic: Retrospective Validation in 563 Localized Prostate Tumors.将预后 DNA 基因组分类器转化为临床应用：563 例局限性前列腺肿瘤的回顾性验证。
Eur Urol. 2017 Jul;72(1):22-31. doi: 10.1016/j.eururo.2016.10.013. Epub 2016 Nov 1.
5
Tissue-based Genomics Augments Post-prostatectomy Risk Stratification in a Natural History Cohort of Intermediate- and High-Risk Men.基于组织的基因组学在中高危男性自然史队列中增强了前列腺切除术后风险分层。
Eur Urol. 2016 Jan;69(1):157-65. doi: 10.1016/j.eururo.2015.05.042. Epub 2015 Jun 6.
6
Fostering shared decision-making about prostate cancer screening among African American men patients and their primary care providers: a randomized behavioral clinical trial.促进非洲裔美国男性患者及其初级保健提供者就前列腺癌筛查进行共同决策：一项随机行为临床试验。
Trials. 2022 Aug 13;23(1):653. doi: 10.1186/s13063-022-06605-1.
7
Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer: An Ancillary Study of the NRG/RTOG 9601 Randomized Clinical Trial.验证一种 22 基因基因组分类器在复发性前列腺癌患者中的应用：NRG/RTOG 9601 随机临床试验的辅助研究。
JAMA Oncol. 2021 Apr 1;7(4):544-552. doi: 10.1001/jamaoncol.2020.7671.
8
The role of genetic markers in the management of prostate cancer.遗传标记物在前列腺癌管理中的作用。
Eur Urol. 2012 Oct;62(4):577-87. doi: 10.1016/j.eururo.2012.05.054. Epub 2012 Jun 5.
9
Supporting informed decision making for prostate specific antigen (PSA) testing on the web: an online randomized controlled trial.在网络上支持关于前列腺特异性抗原（PSA）检测的明智决策：一项在线随机对照试验。
J Med Internet Res. 2010 Aug 6;12(3):e27. doi: 10.2196/jmir.1305.
10
Clinical Utility of Biomarkers in Localized Prostate Cancer.生物标志物在局限性前列腺癌中的临床应用
Curr Oncol Rep. 2016 May;18(5):30. doi: 10.1007/s11912-016-0513-1.

引用本文的文献

1
Associations Between Prostate Magnetic Resonance Imaging, Genomic Testing, and Treatment for Localized Prostate Cancer.前列腺磁共振成像、基因组检测与局限性前列腺癌治疗的相关性研究。
Urol Pract. 2024 Nov;11(6):965-973. doi: 10.1097/UPJ.0000000000000679. Epub 2024 Jul 16.
2
A Novel Modality Enables New Evidence-Based Individual Risk Stratification That Can Potentially Lead to Decisive Management and Treatment Decisions in Prostate Cancer.一种新型方法能够实现基于新证据的个体风险分层，这有可能在前列腺癌中带来决定性的管理和治疗决策。
Diagnostics (Basel). 2023 Jan 24;13(3):424. doi: 10.3390/diagnostics13030424.

本文引用的文献

1
Defining Clinical Utility of Tumor Biomarker Tests: A Clinician's Viewpoint.定义肿瘤标志物检测的临床实用性：临床医生的观点。
J Clin Oncol. 2021 Jan 20;39(3):238-248. doi: 10.1200/JCO.20.01572. Epub 2020 Dec 16.
2
Use of archived specimens in evaluation of prognostic and predictive biomarkers.存档标本在评估预后和预测生物标志物中的应用。
J Natl Cancer Inst. 2009 Nov 4;101(21):1446-52. doi: 10.1093/jnci/djp335. Epub 2009 Oct 8.
3
Clinical trial designs for predictive marker validation in cancer treatment trials.癌症治疗试验中预测性标志物验证的临床试验设计
J Clin Oncol. 2005 Mar 20;23(9):2020-7. doi: 10.1200/JCO.2005.01.112.

G 调试验：构建前列腺生物标志物真实世界有效性的一级证据。

Trials in the Key of G: Building Level 1 Evidence on the Real-world Effectiveness of Prostate Biomarkers.

机构信息

Department of Urology, University of Michigan, Ann Arbor, MI, USA.

Department of Urology, University of Michigan, Ann Arbor, MI, USA; Department of Urology, Mayo Clinic, Rochester, MN, USA.

出版信息

Eur Urol Focus. 2022 Jul;8(4):897-900. doi: 10.1016/j.euf.2022.08.001. Epub 2022 Aug 10.

DOI:10.1016/j.euf.2022.08.001
PMID:35963777
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10566568/
Abstract

A number of genomic classifiers are available to aid in shared decision-making for men with localized prostate cancer; however, there is no high-level evidence assessing their clinical utility. The two randomized controlled trials in this report prospectively evaluate the use of gene expression classifier testing at the time of cancer diagnosis and after surgical treatment.

摘要

有许多基因组分类器可用于帮助局部前列腺癌男性做出共同决策；然而，目前尚无评估其临床效用的高级别证据。本报告中的两项随机对照试验前瞻性地评估了在癌症诊断时和手术治疗后使用基因表达分类器检测的情况。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2231/10566568/33bbd5fafe23/nihms-1928162-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2231/10566568/e8fa9e43998c/nihms-1928162-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2231/10566568/33bbd5fafe23/nihms-1928162-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2231/10566568/e8fa9e43998c/nihms-1928162-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2231/10566568/33bbd5fafe23/nihms-1928162-f0002.jpg